SCHEMBL5656293

SCHEMBL5656293

O=C(O)COc1ccc(OCC=Cc2ccc3c(c2)Cc2cc(C=CCOc4ccc(CC(=O)O)cc4Cl)ccc2-3)c(Cl)c1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 6/20 0.43
TSHR P16473 2/20 0.38
ALOX15 P16050 1/20 0.38
HSD17B10 Q99714 1/20 0.38
TDP1 Q9NUW8 2/20 0.37
LTB4R Q15722 3/20 0.36
LTB4R2 Q9NPC1 3/20 0.36
MCL1 Q07820 1/20 0.36
PPARG P37231 1/20 0.35
RXRA P19793 1/20 0.35
RXRB P28702 1/20 0.35
RXRG P48443 1/20 0.35
LPAR2 Q9HBW0 1/20 0.35
CYP2C19 P33261 1/20 0.34
THRA P10827 1/20 0.34
THRB P10828 1/20 0.34
CSNK2A2 P19784 1/20 0.34
CSNK2B P67870 1/20 0.34
CSNK2A1 P68400 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5656286 1.00 PPARD (0.43) PPARDTSHRALOX15HSD17B10TDP1
SCHEMBL5633915 0.86 PPARD (0.47) PPARDTSHRTDP1LTB4RLTB4R2
SCHEMBL5633913 0.86 PPARD (0.47) PPARDTSHRTDP1LTB4RLTB4R2
SCHEMBL5634293 0.84 PPARD (0.44) PPARD
SCHEMBL5634290 0.84 PPARD (0.44) PPARD
SCHEMBL5633889 0.83 PPARA (0.55) PPARDPPARG
SCHEMBL5633892 0.83 PPARA (0.55) PPARDPPARG
SCHEMBL14539235 0.79 PPARD (0.48) PPARDLTB4RLTB4R2PPARGTHRA
SCHEMBL5633384 0.79 PPARA (0.47) PPARDPPARG
SCHEMBL5633382 0.79 PPARA (0.47) PPARDPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220877-B2 Compounds, their preparation and use NOVO NORDISK A/S (DK) 2007-05-22 US claimed
EP-1438283-A1 DICARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE NOVO NORDISK A/S (DK) 2004-07-21 EP claimed
US-20030109579-A1 Novel compounds, their preparation and use HIGH POINT PHARMACEUTICALS, LLC 2003-06-12 US claimed
WO-2003033453-A1 DICARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND THERAPEUTICAL USE NOVO NORDISK A/S (DK) 2003-04-24 WO claimed
US-7220877-B2 Compounds, their preparation and use NOVO NORDISK A/S (DK) 2007-05-22 US disclosed
EP-1438283-A1 DICARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE NOVO NORDISK A/S (DK) 2004-07-21 EP disclosed
US-20030109579-A1 Novel compounds, their preparation and use HIGH POINT PHARMACEUTICALS, LLC 2003-06-12 US disclosed
WO-2003033453-A1 DICARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND THERAPEUTICAL USE NOVO NORDISK A/S (DK) 2003-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030109579-A1 Novel compounds, their preparation and use PPARG, PPARA, PPARD PPARD 3/4885TSHR 1578/4885ALOX15 699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.